Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren/HCTZ vs Ramipril in Obese Patients with Stage 2 Hypertension
NCT00772577Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren + hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Mean Sitting Systolic Blood Pressure at 8 weeks. Started Aug 2008; status: completed.
02
Drugs
aliskiren + hydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00772577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772577.